Extensive potential pipeline of therapies targeting a range of metabolic diseases and disorders

Future indications

The SiPore® platform allows for the design of specific properties of the silica particles to target different indications. The pipeline of potential products based on the SiPore® platform include: gestational and paediatric type 2 diabetes and obesity, modulation of the gut microbiome, treatment of excessive bile acid levels post bariatric surgery, NASH, weight loss and infantile colicSigrid works collaboratively with research groups at renowned global research institutes to broaden the Company’s pipeline of products.